title: Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.
abstract: OBJECTIVE
  In patients with advanced differentiated thyroid carcinoma (DTC), therapy with the highest safe (131)I activity is desirable to maximize the tumour radiation dose yet avoid severe myelotoxicity. Recently, the European Association of Nuclear Medicine (EANM) published a standard operational procedure (SOP) for pre-therapeutic dosimetry in DTC patients incorporating a safety threshold of a 2 Gy absorbed dose to the blood as a surrogate for the red marrow. We sought to evaluate the safety and effectiveness in everyday tertiary referral centre practice of treating advanced DTC with high (131)I activities chosen primarily based on the results of dosimetry following this SOP.
  
  
  METHODS
  We retrospectively assessed toxicity as well as biochemical and scintigraphic response in our first ten patients receiving such therapy for advanced DTC.
  
  
  RESULTS
  The 10 patients received a total of 13 dosimetrically guided treatments with a median administered activity of 14.0 GBq (range: 7.0-21.4 GBq) (131)I. After 6 of 13 treatments in 6 of 10 patients, short-term side effects of (131)I therapy, namely nausea, vomiting or sialadenitis, were observed. Leukocyte and platelet counts dropped significantly in the weeks after (131)I treatment, but returned to pre-treatment levels by 3 months post-therapy. Serum thyroglobulin levels decreased after 12 of 13 treatments (median reduction: 58%) in 9 of 10 patients.
  
  
  CONCLUSIONS
  In our initial patient cohort, high-activity (131)I therapy for advanced DTC based on pre-therapeutic blood dosimetry following the EANM SOP was safe and well tolerated. Such treatment almost always produced a partial biochemical tumour response.
authors.affiliation: Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Strasse 6, 97080, Würzburg, Germany. verburg_e@klinik.uni-wuerzburg.de
authors.forename: Frederik A
authors.initials: FA
authors.lastname: Verburg
authors.forename: Heribert
authors.initials: H
authors.lastname: Hänscheid
authors.forename: Johannes
authors.initials: J
authors.lastname: Biko
authors.forename: Maria C
authors.initials: MC
authors.lastname: Hategan
authors.forename: Michael
authors.initials: M
authors.lastname: Lassmann
authors.forename: Michael C
authors.initials: MC
authors.lastname: Kreissl
authors.forename: Christoph
authors.initials: C
authors.lastname: Reiners
authors.forename: Markus
authors.initials: M
authors.lastname: Luster
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001772:Blood Cell Count; D002454:Cell Differentiation; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D011829:Radiation Dosage; D011874:Radiometry; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012793:Sialadenitis / Q000209:etiology; D016019:Survival Analysis; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology* / Q000532:radiotherapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes; D013954:Thyroglobulin